High-grade serous ovarian cancers with germline or somatic mutations in BRCA1 or BRCA2 genes and hypermethylation of the BRCA1 gene and NSCLC without ERCC1 are sensitive to platinum compounds [194,195]. The gene discussed is BRCA1; the disease is ovarian serous adenocarcinoma.